REVB delays special stockholder meeting due to lack of quorum

Rhea-AI Filing Summary

Revelation Biosciences (REVB) announced that its Special Meeting of Stockholders held on October 15, 2025 was adjourned to October 29, 2025 because a quorum was not present. The company disclosed this under Regulation FD, noting the information is being furnished, not filed.

The update was provided via an 8-K with an accompanying press release as Exhibit 99.1. The adjournment allows additional time to achieve the required shareholder participation to conduct the meeting’s business.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 10/15/2025 - 12:00 AM Learn about SEC filing dates

FAQ

What did REVB announce in its 8-K?

The Special Meeting of Stockholders on October 15, 2025 was adjourned to October 29, 2025 due to a lack of quorum.

Why was Revelation Biosciences' special meeting adjourned?

A quorum was not present, preventing the company from conducting official meeting business.

When is the rescheduled date for REVB's special meeting?

The meeting is rescheduled for October 29, 2025.

Under which item was this disclosure made?

It was disclosed under Item 7.01 (Regulation FD) and is deemed furnished, not filed.

Did REVB include additional materials with the 8-K?

Yes. A press release (Exhibit 99.1) was included.

What is the ticker for Revelation Biosciences?

Common stock trades as REVB on Nasdaq; warrants trade as REVBW.

false00018105600001810560revb:RedeemableWarrantsEachExercisableForA150400ThShareOfCommonStockAtAnExercisePriceOf579600PerShareMember2025-10-152025-10-1500018105602025-10-152025-10-150001810560us-gaap:CommonStockMember2025-10-152025-10-15

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 15, 2025

REVELATION BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39603	84-3898466
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
4660 La Jolla Village Drive Suite 100
San Diego, California				92122
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 800-3717

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.001 per share		REVB		The Nasdaq Stock Market LLC
Redeemable warrants, each exercisable for a 1/50,400th share of common stock at an exercise price of $579,600 per share		REVBW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On October 15, 2025, Revelation Biosciences, Inc. (the “Company”) issued a press release that its Special Meeting of Stockholders held on October 15, 2025 was adjourned until October 29, 2025 because a quorum was not present. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1, and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1 attached hereto, shall be deemed “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated October 15, 2025
104		Cover Page Interactive Data File (embedded with the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			REVELATION BIOSCIENCES, INC.
Date:	September 15, 2025	By:	/s/ Chester S. Zygmont, III
			Chester S. Zygmont, III Chief Financial Officer (principal financial and accounting officer)